Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy for hypophosphatasia].

Keiichi Ozono1

  • 1Osaka University Graduate School of Medicine, Department of Pediatrics.

Clinical Calcium
|October 2, 2007
PubMed
Summary
This summary is machine-generated.

Hypophosphatasia is a rare genetic bone disorder caused by alkaline phosphatase deficiency. Current therapies manage symptoms, but new treatments like recombinant alkaline phosphatase show promise for future cures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase II study.

Blood advances·2026
Same author

Clinical and Genetic Characterization of Osteogenesis Imperfecta in Japanese Patients: Outcomes of Sequential Bisphosphonate Therapy.

Calcified tissue international·2026
Same author

Real-world Impact of Treatment on Growth in Children With X-Linked Hypophosphatemia.

The Journal of clinical endocrinology and metabolism·2026
Same author

Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome.

Communications biology·2026
Same author

NEFL is associated with inhibition of odontoblastic process in odontohypophosphatasia.

Journal of bone and mineral metabolism·2026
Same author

Pathways to Facilitate Early Recognition and Diagnosis of Hypochondroplasia.

Advances in therapy·2026
Same journal

[The frontier of adipocyte biology, cold environment induces thermogenic genes via epigenomic switch.]

Clinical calcium·2019
Same journal

[Sequential treatment of osteoporosis with anti-sclerostin.]

Clinical calcium·2019
Same journal

[The sequential therapy of romosozumab followed by denosumab for osteoporosis.]

Clinical calcium·2019
Same journal

[Wnt signaling in myeloma.]

Clinical calcium·2019
Same journal

[Fate decision of hematopoietic stem cells by Wnt signaling.]

Clinical calcium·2019
Same journal

[Control of inflammatory bone destruction by targeting the Wnt signaling pathway.]

Clinical calcium·2019
See all related articles

Area of Science:

  • Genetics and Metabolic Disorders
  • Skeletal Biology and Disease

Context:

  • Hypophosphatasia is a congenital disorder impacting bone mineralization due to tissue-nonspecific alkaline phosphatase (ALP) deficiency.
  • This condition presents in various forms, from lethal perinatal to milder infantile, childhood, adult, and odonto types.

Purpose:

  • To review the current understanding of hypophosphatasia, its clinical manifestations, and existing therapeutic approaches.
  • To highlight the limitations of current treatments and explore emerging therapeutic strategies.

Summary:

  • Hypophosphatasia leads to skeletal hypomineralization and rachitic bone changes.
  • Current management focuses on alleviating associated symptoms such as convulsions and hypercalcemia.
  • Bone marrow transplantation has been explored, but challenges remain in donor cell survival; recombinant ALP infusion shows potential in preclinical models.

Related Experiment Videos

Impact:

  • Provides a comprehensive overview of hypophosphatasia for researchers and clinicians.
  • Identifies unmet needs in hypophosphatasia treatment, guiding future research and development.
  • Highlights the potential of novel therapies like recombinant ALP for improving patient outcomes.